Nothing generic about Mayne Pharma
On Tuesday, Mayne Pharma Group Limited (ASX: MYX) announced it had agreed to pay US$652 million ($887 million) for 42 generic drugs from Teva Pharmaceutical Industries and Allergan. The company said the acquired portfolio is expect to contribute sales of US$237 million in FY 2017 and will “propel Mayne Pharma into the top 25 retail generic pharmaceutical companies in the United States”. Shares in Mayne Pharma soared following the announcement, and closed up 31.6% for the week. We own Mayne Pharma as a ‘research driven’ investment for WAM Capital and WAM Research.
Never miss an update
Enjoy this wire? Hit the ‘like’ button to let us know.
Stay up to date with my current content by
following me below and you’ll be notified every time I post a wire
Wilson Asset Management has a track record of making a difference for shareholders and the community for 25 years and is the investment manager for eight LICs - WAM Capital (ASX: WAM), WAM Leaders (ASX: WLE), WAM Global (ASX: WGB), WAM Microcap (ASX: WMI), WAM Alternative Assets (ASX: WMA), WAM Strategic Value (ASX: WAR), WAM Research (ASX: WAX) and WAM Active (ASX: WAA) - and the Wilson Asset Management Leaders Fund. Wilson Asset Management invests over $5 billion on behalf of more than 130,000 retail investors. Wilson Asset Management created and is the lead supporter of the first LICs to deliver both investment and social returns: Future Generation Australia (ASX: FGX) and Future Generation Global (ASX: FGG).
1 stock mentioned
Comments
Comments
Sign In or Join Free to comment
most popular
Equities
This recently triggered market signal has never failed to predict gains
Ophir Asset Management
Equities
I sold my CBA to buy these two financials
Seneca Financial Solutions